Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

Launched by COPENHAGEN RESPIRATORY RESEARCH · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to compare two medications, hydrocortisone and prednisolone, to see which one is more effective and has fewer side effects for treating severe community-acquired pneumonia (CAP) in adults. The main aim is to find out if there is any difference in the overall survival rates of patients within thirty days of treatment. This study will involve participants over the age of 18 who have been diagnosed with severe CAP and for whom their doctor has recommended corticosteroid therapy.

If you are eligible to participate, you will be randomly assigned to receive either hydrocortisone or prednisolone. To join the trial, you must be an adult with severe CAP, but you cannot have certain conditions, such as being pregnant, having active tuberculosis, or having had pneumonia caused by influenza. This trial is not yet recruiting participants, but it is important to know that your health will be monitored closely throughout the study to ensure your safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years
• • Diagnosis of severe CAP for who the physician in charge decides for corticosteroid therapy for severe CAP.
• Exclusion Criteria:
• • Admitted \>24 h
• • Pregnant or breastfeeding women
• • Active tuberculosis or fungal infection
• • Pneumonia caused by influenza
• • Intolerance to either study drug